Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan PK in Acute Migraine vs Inter-Ictal Period
NCT03247790Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lasmiditan in migraine (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration of Lasmiditan at 72 hours and Area Under the Concentration Versus Time Curve From Zero to Infinity of Lasmiditan at 72 hours. Started Aug 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03247790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247790.